Lentigen Technology, Inc. Overview
Pro stress-test →Lentigen Technology, Inc. is a leader in the design, construction and manufacture of lentiviral vectors for clinical application and a subsidiary of Miltenyi Biotec GmbH. The company supports the development of innovative cell therapies targeting rare indications and diseases with high unmet medical need, including difficult-to-treat cancers and autoimmune conditions.
Strategic Profile
Pro stress-test →Lentigen offers end-to-end solutions from preclinical development and vector design to GMP production and serves as the discovery engine for customers' CAR and TCR therapeutic pipelines. Acquired by Miltenyi Biotec in 2014, Lentigen develops and commercializes therapeutics for stem cell therapies and oncology, positioning the company as a critical CDMO partner in cell and gene therapy.
Competitive Landscape
Pro stress-test →Lentigen operates in the specialized lentiviral vector and cell therapy manufacturing CDMO space. Key competitors include Lonza (cell therapy manufacturing), Allogene Therapeutics (CAR-T engineering), and other CDMOs like FUJIFILM Diosynth and Catalent that serve cell and gene therapy developers. Lentigen's differentiation lies in its specialized lentiviral vector expertise and integration within Miltenyi Biotec's broader cell therapy platform.
Industry Context
Lentigen Technology, Inc. operates in Cell and gene therapy CDMO services.
Key facts
Founded: 2004 · Headquarters: Gaithersburg, Maryland · Employees: 41 · Revenue: $4.9M